Updates
Dear Sir/ Madam, This is to inform that as per the assurance given to the shareholders by the management of the Company, we had organized a Factory visit to our Plants (Unit 1 & 2) located in the vicinity of Vapi, Gujarat on Saturday, 04th March, 2017 for the Shareholders who had requested to visit the Plants of the company . This Plant visit was a half day program and limited for 30 people only. Kindly take it on the records and acknowledge the... WHO-Geneva Inspection at Unit - 2
Mangalam Drugs & Organics Ltd has informed BSE that the Company facility at Unit-2 was recently audited by WHO- Geneva and we have been issued few procedural observations. Further the Company shall respond to the same within stipulated time after the receipt of Audit Report. The Company believe that the audit was successful. Standalone Financial Results, Limited Review Report for December 31, 2016
Mangalam Drugs & Organics Ltd has informed BSE about : 1. Standalone Financial Results for the period ended December 31, 20162. Standalone Limited Review for the period ended December 31, 2016 Revenues fall for Mangalam Drugs, improves profit margin
Mangalam Drugs and Organics posted its standalone results for Q3, showing a decline in total income by 4.4% to Rs. 80.35 crore, a slide from the same quarter the previous year. Net profits however increased Rs 3.79 crore in last year's December quarter to Rs. 6.2 crore this Q3, led by loweer operating and inventory costs. Board Meeting Intimation for Results & Closure of Trading Window
Mangalam Drugs & Organics Ltd has informed BSE that the meeting of the Board of Directors of the Company will be held on February 06, 2017, inter alia, to consider and approve the following:- To approve, consider and take on record the Unaudited Financial Results of the company for the quarter and nine months ended December 31, 2016Further, in accordance with Code of Conduct for Prevention of Insider Trading framed by the Company... Shareholding for the Period Ended December 31, 2016
Mangalam Drugs & Organics Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2016. For more details, kindly Click here Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended December 31, 2016
Mangalam Drugs & Organics Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended December 31, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Standalone Financial Results, Limited Review Report for September 30, 2016
Mangalam Drugs & Organics Ltd has informed BSE about : 1. Standalone Financial Results for the period ended September 30, 20162. Standalone Limited Review for the period ended September 30, 2016 Intimation of Credit Ratings assigned
Mangalam Drugs & Organics Ltd has informed BSE regarding "Intimation of Credit Ratings assigned". Board Meeting Intimation for Results & Closure of Trading Window
Mangalam Drugs & Organics Ltd has informed BSE that the meeting of the Board of Directors of the Company will be held on November 10, 2016, inter alia, to consider and approve the following:- To approve, consider and take on record the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2016.Further, in accordance with Code of Conduct for Prevention of Insider Trading framed by the Company...